España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Cellectar Biosciences
CLRB
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$0.2350
-0.00300
-1.26%
At close: -
$0.2380
0.00300
1.28%
After Hours: Dec 20, 7:59 PM EDT
Get Report
Comment
Cellectar Biosciences (CLRB) Forecast
News
Earnings
Cellectar Biosciences (CLRB) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Cellectar Biosciences (NASDAQ:CLRB) Stock
Cellectar Biosciences Stock (NASDAQ: CLRB)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Wednesday, December 11, 2024
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Insights
Crude Oil Jumps 2%; Macy's Lowers Earnings Forecast
Avi Kapoor
Oppenheimer Downgrades Cellectar Biosciences ...
Benzinga Newsdesk
Cellectar Biosciences Stock Plunges As Cancer-Focused Cancer Firm Pursues Strategic Options
Vandana Singh
Nasdaq Surges Over 1%; US Inflation Rises In-Line With Expectations
Avi Kapoor
Cellectar Biosciences shares are trading lowe...
Benzinga Newsdesk
Why Stitch Fix Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket
Avi Kapoor
Tuesday, December 10, 2024
Trading Halt: Halt status updated at 5:25:00 ...
Benzinga Newsdesk
Cellectar Biosciences Expects Strategic Repri...
Benzinga Newsdesk
Cellectar Biosciences Seeks Strategic Options...
Benzinga Newsdesk
Trading Halt: Halted at 4:55:00 p.m. ET - Tra...
Benzinga Newsdesk
Thursday, November 21, 2024
NorthStar Medical Radioisotopes Announces The...
Benzinga Newsdesk
Tuesday, November 19, 2024
Oppenheimer Maintains Outperform on Cellectar...
Benzinga Newsdesk
Monday, November 18, 2024
Cellectar Biosciences' Q3 Cash And Cash Equiv...
Benzinga Newsdesk
Cellectar Biosciences Q3 2024 GAAP EPS $(0.40...
Benzinga Newsdesk
Earnings Scheduled For November 18, 2024
Benzinga Insights
Thursday, November 14, 2024
Cellectar Biosciences Signs Supply Agreement ...
Benzinga Newsdesk
Tuesday, November 12, 2024
Cellectar Biosciences And SpectronRx Have Sig...
Benzinga Newsdesk
Friday, November 01, 2024
Cellectar Biosciences Received A Letter From ...
Benzinga Newsdesk
Friday, October 11, 2024
Oppenheimer Reiterates Outperform on Cellecta...
Benzinga Newsdesk
Monday, August 26, 2024
Reported Friday, Cellectar Biosciences Announ...
Benzinga Newsdesk
Tuesday, August 13, 2024
Cellectar Biosciences Says Its Cash Balance O...
Benzinga Newsdesk
Tuesday, July 23, 2024
Gold Moves Higher; Coca-Cola Increases FY24 Forecast
Avi Kapoor
Why Comcast Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Avi Kapoor
Crude Oil Down 2%; GE Aerospace Earnings Top Views
Avi Kapoor
Cancer-Focused Cellectar Biosciences Stock Trades Lower Despite Meeting Goal In Blood Cancer Study
Vandana Singh
Cellectar Biosciences shares are trading lowe...
Benzinga Newsdesk
Cellectar Biosciences' Iopofosine I 131 Excee...
Benzinga Newsdesk
Monday, July 22, 2024
Cellectar Biosciences shares are trading high...
Benzinga Newsdesk
Cellectar Biosciences Generates $19.4M, Poten...
Benzinga Newsdesk
Wednesday, May 29, 2024
Cellectar Biosciences Partners With City Of H...
Benzinga Newsdesk
Friday, May 24, 2024
Cellectar Biosciences Files $300M Mixed Secur...
Benzinga Newsdesk
Tuesday, May 14, 2024
Cellectar Biosciences' Cash and Cash Equivale...
Benzinga Newsdesk
Cellectar Biosciences Q1 2024 GAAP EPS $(0.74...
Benzinga Newsdesk
Thursday, March 28, 2024
Roth MKM Maintains Buy on Cellectar Bioscienc...
Benzinga Newsdesk
Oppenheimer Reiterates Outperform on Cellecta...
Benzinga Newsdesk
Wednesday, March 27, 2024
Cellectar Biosciences Says Cash and Cash Equ...
Benzinga Newsdesk
Cellectar Biosciences Q4 EPS $(0.40) Beats $(...
Benzinga Newsdesk
Earnings Scheduled For March 27, 2024
Benzinga Insights
Tuesday, March 26, 2024
Earnings Preview For Cellectar Biosciences
Benzinga Insights
Monday, March 04, 2024
Cellectar Biosciences Is An 'Attractive Acquisition Target' According To This Analyst - Here's Why
Vandana Singh
Roth MKM Reiterates Buy on Cellectar Bioscien...
Benzinga Newsdesk
Cellectar Biosciences Announced That Iopofosi...
Benzinga Newsdesk
Tuesday, January 30, 2024
Cellectar Biosciences Has Enrolled The First ...
Benzinga Newsdesk
Thursday, January 25, 2024
Cellectar Biosciences Says Tranche A Warrants...
Benzinga Newsdesk
Monday, January 22, 2024
Cellectar Biosciences' Iopofosine I 131, Demo...
Benzinga Newsdesk
Tuesday, January 16, 2024
Cellectar Biosciences Announced Preclinical D...
Benzinga Newsdesk
Thursday, January 11, 2024
Cellectar Biosciences Has Partnered To Advanc...
Benzinga Newsdesk
Monday, January 08, 2024
Cellectar Biosciences shares are trading high...
Benzinga Newsdesk
Why Is Cancer-Focused Cellectar Biosciences Stock Trading Higher Today?
Vandana Singh
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch